IN8BIO INC. - COMMON STOCK

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

12 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

29 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

26 Sep 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

19 Sep 2023 07:03:33 By Nasdaq GlobeNewswire

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

15 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 Aug 2023 15:15:37 By Nasdaq GlobeNewswire

IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

17 May 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

12 May 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting

02 May 2023 16:08:00 By Nasdaq GlobeNewswire

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

01 May 2023 07:00:00 By Nasdaq GlobeNewswire

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting

26 Apr 2023 09:00:10 By Nasdaq GlobeNewswire

IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023

24 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023

17 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting

11 Apr 2023 07:00:02 By Nasdaq GlobeNewswire

IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

30 Mar 2023 15:15:00 By Nasdaq GlobeNewswire